Beacon Biosignals的封面图片
Beacon Biosignals

Beacon Biosignals

软件开发

Boston,MA 7,786 位关注者

Our mission is to improve human health by enabling rapid, targeted interventions through advanced brain analytics.

关于我们

Beacon's AI platform for brain data enables and accelerates new treatments that transform the lives of patients with neurological and psychiatric disease. Through FDA-cleared EEG wearables, novel machine learning algorithms, enormous datasets, and advances in software engineering, we are changing the way patients are treated for disorders of the brain. Want to join the team? We’re hiring—check out the careers page on our website for more. Please be advised that Beacon Biosignals does not ask for personal information outside of our official hiring process. If a role is not listed on our careers page, it is not an active job opening. We will never ask candidates to send money to supplement company equipment, and all official emails from our team will come from the @beacon.bio domain, never text messages or Teams messages.

网站
https://beacon.bio
所属行业
软件开发
规模
11-50 人
总部
Boston,MA
类型
私人持股
创立
2019

地点

Beacon Biosignals员工

动态

  • Beacon Biosignals转发了

    查看David Matthews, PhD的档案

    CBO @ Beacon Biosignals | Former BCG Partner, BrightInsight CCO | PhD Computational Neuroscience

    We're now #hiring for two more key roles on our commercial team at Beacon Biosignals. We are deeply technical across neuroscience and machine learning, motivated by our opportunity to transform clinical development alongside our life science partners, and inspired to help people with psychiatric, neurological, and sleep conditions. We're also growing. A lot. The best-fit candidates will use their scientific, strategic, and commercial experience to execute on our growth goals with speed and precision. These roles will report directly to me, but please apply through our normal recruiting channels or contact our recruiter Jake Fischer. Please forward to anyone who would be interested and a good fit!

    此处无法显示此内容

    在领英 APP 中访问此内容等

  • 查看Beacon Biosignals的组织主页

    7,786 位关注者

    ?????????????????? ?????????????? ???????????????????? & ???????? ?????????????? ???????? ????????????’?? ?????????? ???? ?????? ???????????????? Clinical trials depend on high-quality, reliable data—but when it comes to sleep studies, traditional in-lab polysomnography (PSG) presents significant challenges. PSG is burdensome for patients, leading to poor usability scores and potential disruptions in natural sleep patterns. ?? New data confirms that patients overwhelmingly prefer Beacon's Dreem 3S headband over PSG in clinical trials, as shown in System Usability Scale (SUS) scores (first image). The Dreem 3S provides PSG-equivalent data in an at-home, consumer-grade device designed for patient comfort. A better patient experience translates to higher compliance and more consistent data collection. ?? Because Dreem 3S eliminates the "first night" effect, baseline sleep data is more reliable from the start (second image). In contrast, the unfamiliar lab environment of PSG often disrupts sleep on the first night, potentially skewing results. By improving usability and reducing study complexity, Dreem 3S enables more scalable, patient-friendly, and data-rich CNS clinical trials. Contact us to learn more about the Deem 3S EEG Headband: https://lnkd.in/errYwFaE #EEG #CNSDrugDevelopment #SleepResearch #ClinicalTrials #PrecisionMedicine?

    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
  • 查看Beacon Biosignals的组织主页

    7,786 位关注者

    ?? It’s World Sleep Day! While we often think of sleep as a time for rest and cognitive recovery, it’s also a powerful window into brain activity and overall health. Sleep patterns can reveal underlying neurological and systemic conditions—sometimes years before other symptoms appear—making it a critical focus for disease research and treatment. ?????? ?????????? ?????????????? ???? ?????????????? ????????????????? Sleep is a structured neurophysiological state that provides a unique opportunity to detect changes linked to primary sleep disorders, CNS diseases, secondary sleep disorders, and therapeutic interventions. Understanding these changes can drive breakthroughs in research and treatment development in the following areas: ?? Primary Sleep Disorders? Conditions like obstructive sleep apnea (OSA), narcolepsy, and idiopathic hypersomnia impact millions, often going undiagnosed for years. Left untreated, these disorders can lead to cognitive impairment, cardiovascular disease, and metabolic dysfunction. ?? CNS Diseases? Sleep disruptions are closely tied to depression, schizophrenia, bipolar, PTSD, Alzheimer’s, Parkinson’s, and other neurological conditions. Changes in sleep architecture—such as fragmented REM sleep or altered slow-wave activity—can reflect disease progression and even precede clinical symptoms. ?? Secondary Sleep Disorders? Chronic conditions like pain, inflammatory bowel disease (IBD), and atopic dermatitis often lead to severe sleep disturbances, which in turn exacerbate inflammation, pain perception, and immune function, creating a cycle that worsens overall health. ?? This #WorldSleepDay wraps up National Sleep Foundation's Sleep Awareness Week, a time to recognize that sleep is more than just a necessity—it’s a key to understanding disease and improving long-term health outcomes. #SleepHealth #WorldSleepDay #SleepAwarenessWeek #Neuroscience #CNSResearch #BrainHealth

    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
      +1
  • 查看Beacon Biosignals的组织主页

    7,786 位关注者

    ?????? ????????’?? ?? ??????(??)! ???????? ???????? ?????????????????? ???? ?????? ???????? ?????????????? ?????????????? ???????? ???????? ???? ?????? ???????????? ???????????????????????? ???????? ?????? ?????? ???????????? ???????? ??????????????????????????. ????????’?? ???????? ???? ??????????????. Regulatory frameworks for AI-driven medical devices are evolving rapidly, and staying ahead of these changes is critical. Our VP of Analytics and Machine Learning, Alexander Chan, recently spoke at a RAPS Indiana Chapter meeting about the latest FDA guidance on Predetermined Change Control Plans (PCCPs)—a key component of AI/ML-powered medical device submissions. The final 2024 FDA guidance introduced several notable changes from the draft version earlier in the year: ?? ?????????????? ???????????????? ???? ?????????????????????? ?????? ?????? → More flexibility in how devices can be positioned.? ?? ???????????????? ???????????????????? ?????????????????????? → PCCP authorization can be withheld if a manufacturer has a history of non-compliance.? ?? ?????????????? ???????????????? ???? ???????????????? → Ensuring transparency in PCCP updates.? ?? ?????? ???????????????????????? ?????? ???????????????????? ???????? ???????????????????? → Ongoing performance evaluation is now recommended. A key takeaway? The FDA continues to proactively refine its approach, collaborating with innovators, and making regulatory submissions more interactive throughout the process. Check out our VP’s recommendation for a PCCP submission and read more about how Beacon Biosignals' two PCCPs below.? ???Beacon's Dreem 3S PCCP Clearance: https://lnkd.in/ghZ-fcMu ???Beacon's SleepStageML Clearance: https://lnkd.in/g_2bWkGG #AIinHealthcare #RegulatoryAffairs #MachineLearning #MedicalDevices #FDA #PCCP

    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
  • SYNGAP Research Fund x Beacon Biosignals: Advancing ASO Therapy with EEG We’re proud to partner with the incredible team at SynGAP Research Fund (SRF) for SYNGAP1-Related Disorders as they push forward groundbreaking research and advocacy for patients with SYNGAP1. SRF’s research team is using Beacon’s FDA 510(k)-cleared EEG headband to assess sleep biomarkers in specific patient populations receiving novel ASO (antisense oligonucleotide) therapies for SYNGAP1. Recently, Beacon Biosignals’ Medical Director, Jay Pathmanathan, MD, PhD, presented on how SRF is using EEG data to: ?? Identify optimal candidates for ASO therapy trials with real-time brain activity insights. ?? Predict seizure risks and treatment responses using EEG-driven biomarkers. ?? Accelerate trial timelines—shifting insights from years to hours. By integrating genetic insights with EEG technology, we’re enhancing ASO therapy trials—ensuring both safety and efficacy for those who need it most. ?? Watch Dr. Pathmanathan’s full webcast & learn more about SRF’s innovative work: ?https://lnkd.in/gKTdNBYq #ASOTherapy #EEG #PrecisionMedicine #SYNGAP1 #EpilepsyResearch #ClinicalTrials #Neurotech

  • Beacon Biosignals转发了

    查看Jacob Donoghue, MD PhD的档案

    Co-Founder & CEO // Beacon Biosignals (We’re hiring!)

    “I’m tired of having hope— I want a cure.” This powerful quote from a caregiver of someone living with a rare disease resonates deeply with me and drives everything we do at Beacon Biosignals. The lived experiences of patients and caregivers facing the unimaginable are the motivation behind our work. We know that cures come from data, and we’re accelerating our efforts because speed is critical for these families. I’ve heard firsthand the traumatic stories about the obstacles patients face just to get EEGs and sleep monitoring (e.g. the screaming during the hour it takes to apply the electrodes, the gel and glue in hair for weeks, the 3 months wait until getting EEG scheduled, the electrodes falling off and needing to reschedule *another* 3 months later, the physical restraints placed to hold down a screaming child during application, the list goes on….) That’s why I’m proud of the role we’re playing in ensuring every patient’s brain can be analyzed and understood easily, at-home, and applied by patients themselves and their caregivers. Next up: Characterizing brain activity and sleep physiology in #SYNGAP1 and pushing to get new treatments to patients faster than ever. It’s time for a cure!

  • Exciting news! Beacon Biosignals is expanding our industry-leading Clinical Operations team to further support our biopharma partners in integrating EEG technology into early- and late-stage clinical trials. From trial design to data analysis and delivery, we ensure the highest-quality data to drive better clinical outcomes. This week we’re thrilled to welcome Emily Mitchell as our new Vice President of Clinical Study Operations! Emily joins Beacon from ICON plc where she served as VP, General Parter and former head of the Decentralized Clinical Trials team. She brings extensive experience in operational oversight and department scaling, enhancing operational processes and market presence, and support of cross functional business development activities. Emily is looking forward to growing Beacon's study operations and supporting a growing client relationship base.? ? Interested in joining Beacon Biosignals? We’re hiring brilliant minds to help us build the future of precision neuroscience. Check out our careers page for more! https://beacon.bio/careers?

    • 该图片无替代文字
  • 查看Beacon Biosignals的组织主页

    7,786 位关注者

    ?? Last chance to register: Navigating FDA PCCP Authorization for AI-Driven Medical Devices ?? Tune in tomorrow, February 27, from 4:30-6:00 PM ET to a webcast hosted by the Regulatory Affairs Professionals Society, RAPS Indiana Chapter! The talk will focus on navigating the FDA’s latest guidance on Predetermined Change Control Plans (PCCPs) for AI-driven medical devices. ?? ???????????????? ??????????????:? Alexander Chan, PhD, VP of Analytics and Machine Learning at Beacon Biosignals Prior to joining Beacon, Alex led the Health Technologies algorithm team at Apple, delivering sleep tracking for the Apple Watch and developing groundbreaking machine learning models for next-gen sleep sensing. He holds a PhD in Medical Engineering and Medical Physics from the Harvard/MIT Division of Health Sciences. ?? ???????? ???? ????????????:? ? Insights on regulatory pathways for AI in healthcare, including the significance of PCCP clearance? ? Strategies for continuous innovation in medtech and key factors the FDA evaluates when assessing PCCPs for AI-enabled medical devices ? Live Q&A with Alex on Beacon’s experience achieving two PCCP clearances ?? ?????? ???? ????????????:? This event is open to both members and non-members of RAPS. ?? Attend in person: Barnes & Thornburg, Indianapolis? ?? Join virtually: Link will be provided before the event ?? Secure your spot now! Register here: https://lnkd.in/gjfKdmMU #AI #MedicalDevices #RegulatoryAffairs #FDA #MachineLearning #PCCP

  • 查看Beacon Biosignals的组织主页

    7,786 位关注者

    “Neuroscience...stands out as a therapeutic area that greatly benefits from the incorporation of wearables due to the limitations of current subjective and infrequent endpoints and biomarkers... This creates a strong need to gather more objective data to support better-informed clinical decisions. Furthermore, the shift from merely treating symptoms to implementing disease-modifying approaches demands a precision and understanding that current clinical or cognitive biomarkers simply cannot provide.” In a recent Clinical Tech Leader interview, Bryan J. Hansen, Ph.D., Director of Innovative Health at Johnson & Johnson Innovative Medicine, discusses why scalability, reduced participant burden, real-world insights, and clinically rigorous, objective data make wearables, particularly sleep measurement, essential for decentralized neuroscience trials. Read the full interview here: https://lnkd.in/ejhSWrN6 #Neuroscience #Wearables #DecentralizedTrials #CNSDrugDevelopment

  • 查看Beacon Biosignals的组织主页

    7,786 位关注者

    ???????????? ???????????? ????????: ?????? ?????????? ???????? ???????????? ?????? ??????-??/?????? ???????? ??????????????????????? With the market for GLP-1/GIP receptor agonists rapidly expanding, how can new treatments stand out? The key may lie in parallel treatment of interrelated comorbidities based on secondary clinical endpoints, potentially improving quality of life for patients while expanding drug labeling. ???????? ?????????????????????? ?????????? ?????????? (??????): ??? Affects 40%+ of adults with BMI >30—and up to 90% in cases of severe obesity (Patial et. Al., 2023) ??? Impacts sleep fragmentation, energy levels, and metabolic health ??? Regulators like the FDA already accept EEG-based sleep endpoints in Phase 3 trials and drug labeling (e.g., Wake After Sleep Onset, Sleep Efficiency) ???? ?????????????????????????? ?????????? ???????????????????? ???? ???????????????? ????????????, ???????? ???????????????????? ??????:? ?1. Optimize trial design through better patient stratification? ?2. Expand drug labeling into CNS disorders affecting sleep quality?? ?3. Use at-home EEG to make sleep tracking easier, cheaper, and scalable? Check out this article on how Skye Bioscience Inc. is integrating sleep endpoints in their Phase 2 trial of Nimacimab for obesity to provide a more comprehensive assessment of its therapeutic potential: https://lnkd.in/d9WET6FN Measuring sleep physiology isn’t just about collecting more trial data—it’s about demonstrating novel, clinically meaningful endpoints to better differentiate in an increasingly competitive GLP-1/GIP market. #EEG #GLP1 #GIP #incretin #OSA #CNSDrugDevelopment #Biopharma

相似主页

查看职位